Pioneering RNA Modification Beyond Rare Diseases by Exploring Novel Editing Technologies & Targeting Multiple Mutations to Remove the Barriers to Treating Common Diseases
- Rethinking editing machinery to edit beyond point mutations and specifically modify multiple target sites simultaneously
- Preclinical data to demonstrate the potential of RNA editing outside of rare disease
- Strategically investigating common disease targets to attract investment and pharma partnerships